Latest Neuroendocrine tumor Stories
EAST HANOVER, N.J., Feb.
Scientists at Johns Hopkins have deciphered the genetic code for a type of pancreatic cancer, called neuroendocrine or islet cell tumors.
BERLIN, January 21, 2011 /PRNewswire-FirstCall/ -- Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a firm specializing in radioactive compounds for the treatment of cancer, has renewed the approval of its drug YTTRIGA (Yttrium-90 chloride) by the European Commission.
BOSTON, Jan. 20, 2011 /PRNewswire-USNewswire/ -- Through a grant provided by the Caring for Carcinoid Foundation (www.caringforcarcinoid.org), researchers at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center have discovered several key mutations in pancreatic neuroendocrine tumors.
John Hopkins University researchers said on Thursday that they have discovered the reason some people are able live for years with the same kind of rare pancreatic cancer that has inflicted people like Apple's CEO Steve Jobs.
NEW YORK, Dec. 2, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
COLUMBIA, Md., Nov. 2, 2010 /PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN) today announced that the company has been awarded a $244,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program under The Patient Protection and Affordable Care Act of 2010 (PPACA).
The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.
NEW YORK, Oct. 12 /PRNewswire/ -- The World NET Community announces the first Worldwide NET Cancer Awareness Day on November 10, 2010 to raise awareness about cancers called neuroendocrine tumors (NETs) and the need for timely detection and diagnosis.
EAST HANOVER, N.J., Sept.